Dronabinol Interactions With Cognitive Enhancing Drug in Humans

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2009-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Marijuana use is a major problem among veterans and non-veterans. A patient's use of marijuana while engaged in psychotherapy treatment may affect their memory and, therefore, limit their ability to benefit from treatment. This study is designed to test a new pharmacotherapy, modafinil, which has the potential to improve memory functioning in marijuana using individuals.

We hypothesize that modafinil treatment will decrease ratings of drug liking and improve cognitive measures, especially episodic memory.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Dronabinol Treatment for Depression and/or Anxiety in Older Patients

NCT03369639

Depression, Anxiety

WITHDRAWN

Ph1 Marinol Interaction Study - Part 2 - 1

NCT00490269

Marijuana Dependence

COMPLETED PHASE1

Ph1 Marinol Interaction Study - Part 1 - 1

NCT00438139

Marijuana Dependence

TERMINATED PHASE1

The Effect of Dronabinol on the Acquisition and Consolidation of Trauma-Associated Memories

NCT04871269

Intrusive Memories

ACTIVE_NOT_RECRUITING NA

Activation of the Endocannabinoid System and Cognition

NCT05226351

Post Traumatic Stress Disorder

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The impairment of episodic memory in marijuana abusers has important treatment implications. Since many treatments, including cognitive-behavioral therapy, strongly utilize episodic memory, marijuana use during treatment may lead to diminished treatment outcomes. In addition, lessened response inhibition may lead to elevated rates of drug relapse while in treatment. Consequently, a treatment which will improve episodic memory and response inhibition may lead to improved treatment outcomes in marijuana users. One such treatment is modafinil.This study will be a 4 session within-subjects, double-blind, crossover study evaluating the impact of modafinil (400 mg/day) on the cognitive, subjective, and physiological effects of marijuana. Across 4 sessions, subjects will be randomly assigned to receive either oral placebo, modafinil (400mg), dronabinol (15mg), or dronabinol and modafinil. Outcome measures will include physiological, cognitive, and subjective drug effects.

Currently this study complete and has been published.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cannabis Marijuana Abuse

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

drug condition

Participants received each drug condition in sequential order across 4 test days. Not all participants received the interventions in the same order.

Group Type OTHER

drug condition

Intervention Type DRUG

Dronabinol (15mg) or Modafinil (400mg) or Dronabinol + Modafanil or placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

drug condition

Dronabinol (15mg) or Modafinil (400mg) or Dronabinol + Modafanil or placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Marinol, Provigil,

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Males and females between 18 and 55 years old will be eligible for this study.

* Marijuana used at least once in last 2 months and at least 10 times in lifetime.
* Subjects do not meet DSM-IV criteria for marijuana abuse or dependence.
* Subjects are NOT seeking treatment for substance abuse or dependence.
* Females must not be pregnant as determined by pregnancy screening, nor breast feeding, and must be using acceptable birth control methods other than oral contraceptive pills (OCP). Modafinil may cause OCP to be ineffective. Acceptable forms of birth control are condoms, diaphragms, and IUDs.
* No alcohol or drugs 24 hours prior to testing session.
* Subjects must agree to not drive to or from session.

Exclusion Criteria

* • History of heart disease, left ventricular hypertrophy, ischemic ECG changes, chest pain, arrhythmia, hypertension.

* History of severe renal or hepatic diseases.
* History of psychosis, schizophrenia or bipolar type I disorder.
* History of seizure disorder.
* Current diagnosis of alcohol and other drug dependence (other than nicotine).
* A positive urine toxicology result for cocaine or opiates at intake.
* Current use of over-the-counter or prescription psychoactive drugs (antidepressant, anxiolytics, antipsychotics, mood stabilizers, psychostimulants).
* Liver function tests (ALT or AST) greater than 3 times normal.
* Known allergy to modafinil or dronabinol.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No